Ciloa Bio

Executive Summary

Ciloa Bio is a French biotechnology company pioneering the bioengineering of small extracellular vesicles (sEVs, or exosomes) as delivery vehicles for novel therapeutics and vaccines. Founded in 2016 and headquartered in Montpellier, the company leverages the natural targeting abilities of exosomes to deliver therapeutic proteins—such as adiponectin—to treat metabolic diseases, oncology, rare diseases, and viral threats. Its core platform enables the loading of biologic cargos into sEVs, resulting in potent, stable, and potentially affordable drugs. By harnessing the body's own intercellular communication system, Ciloa aims to overcome key limitations of conventional biologic therapies, including poor stability, immunogenicity, and high production costs. Ciloa's technology addresses a large and growing market for targeted drug delivery, with applications spanning multiple therapeutic areas. The company's exosome-based approach offers a differentiated advantage over synthetic delivery systems (e.g., lipid nanoparticles) in terms of biocompatibility and cell-type specificity. While Ciloa remains in preclinical stages with no disclosed funding rounds or partnerships, its focus on clinically validated targets like adiponectin positions it for potential licensing deals or collaborations with larger pharmaceutical companies. The successful development of its lead programs could unlock significant value in the biologic drug delivery space, particularly for metabolic and oncologic indications. However, as a private, early-stage biotech, Ciloa faces typical risks around manufacturing scalability, regulatory pathway, and competition from other exosome platforms.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept for lead exosome-based therapy65% success
• Q3 2026Series A financing round50% success
• Q4 2026First licensing or co-development partnership40% success